基于 14-CpG 的signature 可改善肝细胞癌患者的预后预测。
14-CpG-Based Signature Improves the Prognosis Prediction of Hepatocellular Carcinoma Patients.
机构信息
Department of Clinical Laboratory, Shunde Hospital, Southern Medical University (the First People's Hospital of Shunde), Foshan 528300, Guangdong Province, China.
Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, Guangdong Province, China.
出版信息
Biomed Res Int. 2020 Jan 8;2020:9762067. doi: 10.1155/2020/9762067. eCollection 2020.
BACKGROUND
Epigenetic dysregulation via alteration of DNA methylation often occurs during the development and progression of cancer, including hepatocellular carcinoma (HCC). In the past, many patterns of single-gene DNA methylation have been extensively explored in the context of HCC prognosis prediction. However, the combined model of a mixture of CpGs has rarely been evaluated. In the present study, we aimed to develop and validate a CpG-based signature model for HCC patient prognosis.
METHODS
Data from methylation profiling of GSE73003, GSE37988, and GSE57958 from the Gene Expression Omnibus (GEO) database and 371 HCC patients from the Cancer Genome Atlas (TCGA) were downloaded. The 371 HCC patients were randomly divided into a development cohort ( = 263) and a validation cohort ( = 263) and a validation cohort (.
RESULTS
Fourteen differential CpGs associated with OS were identified in HCC patients. The MSH, based on these 14 differential CpGs, could effectively divide HCC patients into two distinct subgroups with high risk or low risk of death ( < 0.0001) in the development cohort (26.35 vs 83.18 months, HR = 3.83, 95% CI: 2.56-5.90, < 0.0001) in the development cohort (26.35 vs 83.18 months, HR = 3.83, 95% CI: 2.56-5.90, < 0.0001) in the development cohort (26.35 vs 83.18 months, HR = 3.83, 95% CI: 2.56-5.90.
CONCLUSION
The 14-CpG-based signature is significantly associated with OS and may be used as a novel prognostic biomarker for HCC patients.
背景
表观遗传调控通过改变 DNA 甲基化在癌症的发生和发展中经常发生，包括肝细胞癌（HCC）。过去，在 HCC 预后预测的背景下，广泛探索了许多单基因 DNA 甲基化模式。然而，CpG 混合的组合模型很少被评估。在本研究中，我们旨在开发和验证基于 CpG 的 HCC 患者预后签名模型。
方法
从基因表达综合数据库（GEO）的 GSE73003、GSE37988 和 GSE57958 下载甲基化谱数据，并从癌症基因组图谱（TCGA）下载 371 例 HCC 患者的数据。将这 371 例 HCC 患者随机分为开发队列（n=263）和验证队列（n=263）。
结果
在 HCC 患者中鉴定出 14 个与 OS 相关的差异 CpG。基于这 14 个差异 CpG 的 MSH，能够有效地将 HCC 患者分为高风险或低死亡风险两个亚组（<0.0001）在开发队列（26.35 vs 83.18 个月，HR=3.83，95%CI：2.56-5.90，<0.0001）在开发队列（26.35 vs 83.18 个月，HR=3.83，95%CI：2.56-5.90，<0.0001）在开发队列（26.35 vs 83.18 个月，HR=3.83，95%CI：2.56-5.90。
结论
基于 14-CpG 的特征与 OS 显著相关，可能作为 HCC 患者的一种新的预后生物标志物。
Zotero 插件